Mesothelioma Trial, Recruiting NCT04981119 Sponsor: A2 Biotherapeutics Inc. Condition: Mesothelioma
Back to Mesothelioma

Mesothelioma Trial, Recruiting

NCT04981119
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Part 1:

  • You have been diagnosed with a confirmed solid tumor — such as colorectal cancer, non-small cell lung cancer, or pancreatic cancer — that has spread to other parts of the body, cannot be surgically removed, or where your doctor believes there is a high risk it could come back in a way that cannot be cured within two years.

Part 2 (additional requirements):

  • You have been diagnosed with a confirmed solid tumor — such as colorectal cancer, non-small cell lung cancer, pancreatic cancer, mesothelioma, or ovarian cancer — that has spread, cannot be surgically removed, or carries a high risk of incurable relapse within two years.
  • A specific genetic marker called HLA-A*02 has been found in your inherited DNA through a special blood test (confirm with trial site).
  • Testing of your tumor tissue has shown a specific genetic change related to HLA-A*02 (confirm with trial site).
  • You are generally well enough to carry out light activity and care for yourself — your doctor has rated your physical wellbeing as 0 or 1 on a standard scale (confirm with trial site).

Who may not be able to join:

  • You have been diagnosed with another type of cancer in the past 5 years — with exceptions for certain low-risk cancers such as some skin cancers, low-grade localized prostate cancer, superficial bladder cancer, early-stage breast or cervical changes (DCIS or CIS), or Stage I uterine cancer.
  • You have previously received a stem cell transplant from another person (a donor).
  • You have previously received a transplanted solid organ (such as a kidney, liver, or heart).
  • (Part 2 only) You have received any cancer treatment or experimental therapy — including chemotherapy, targeted drugs, antibody treatments, or certain types of radiotherapy — within 2 weeks before a planned procedure to collect your blood cells, or within a timeframe based on the specific drug used, whichever is shorter (confirm with trial site).
  • (Part 2 only) You currently have an active infection caused by bacteria, a virus, a fungus, or another organism that requires specific treatment, or you have recently been hospitalized or treated with intravenous antibiotics for a serious infection.
  • (Part 2 only) You have active cancer that has spread to your brain or central nervous system — though people who have previously been treated for brain metastases may be considered with special approval (confirm with trial site).
  • (Part 2 only) Your doctor believes, for any reason, that you would not be able to complete all required visits, procedures, or follow-up appointments as part of the study.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Eric W Ng, MD, FAAP, A2 Biotherapeutics Inc.

Phone: (310)431-9180

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
A2 Biotherapeutics Inc.
Registry
ClinicalTrials.gov
Start date
29 October 2021
Est. completion
1 December 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Percentage of participants who can enroll in an A2 Biotherapeutics, Inc. CAR T-cell therapy study after undergoing apheresis; Percentage of screened participants experiencing loss of heterozygosity (LOH) of HLA-A*02 identified by next generation sequencing

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov